Comparative Pharmacology
Head-to-head clinical analysis: HYDROXOCOBALAMIN versus RUBIVITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXOCOBALAMIN versus RUBIVITE.
HYDROXOCOBALAMIN vs RUBIVITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxocobalamin is a precursor of methylcobalamin and adenosylcobalamin, which are essential cofactors for methionine synthase and methylmalonyl-CoA mutase. It facilitates the conversion of homocysteine to methionine and methylmalonyl-CoA to succinyl-CoA, and neutralizes cyanide by forming cyanocobalamin.
Hydroxocobalamin is a synthetic form of vitamin B12 that acts as a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, erythrocyte maturation, and neurological function. In cyanide poisoning, it binds cyanide ions to form nontoxic cyanocobalamin, which is excreted renally.
1000 mcg intramuscularly once daily for 1 week, then weekly for 1 month, then monthly. For maintenance: 1000 mcg intramuscularly once monthly. Route: IM.
1000 mcg intramuscularly or deep subcutaneous injection once daily for 5-7 days, then 100-1000 mcg monthly for maintenance.
None Documented
None Documented
Terminal elimination half-life: ~26-31 days. After high-dose therapy, plasma levels decline more rapidly initially (α-phase half-life ~6 hours) due to distribution, followed by slow terminal elimination reflecting tissue release. Clinically, this supports monthly dosing for deficiency correction.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 24-48 hours in severe impairment)
Primarily renal excretion (50-90% as unchanged drug). Biliary/fecal elimination accounts for <10%.
Primarily renal; ~50-80% of absorbed dose excreted unchanged in urine within 24 hours; biliary/fecal excretion accounts for minor fraction (<10%)
Category C
Category C
Vitamin B12 Supplement
Vitamin B12 Supplement